-
Orforglipron
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Orforglipron 2212020-52-3 Dec, 2026 Sep.26, 2037 estimated PV Completion – Sep, 2026 [Product]
Provide the API as well as the SDD (Spray Dried Dispersion)
[Indication]
1. Type 2 diabetes mellitus:To improve glycemic control in adults with type 2 diabetes mellitus.
2. For clinical research, now it can be used for Chronic weight management in adults.
-
Osimertinib
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Osimertinib Mesylate 1421373-66-1 Oct, 2026 Aug.8, 2032 estimated PV Completion - Aug, 2026 [Indication]
1. For the adjuvant treatment of patients with non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R mutation.
2. For the first-line treatment of adults with metastatic or locally advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation.
3. For the treatment of adults with locally advanced or metastatic NSCLC who have disease progression after treatment with EGFR-TKI and whose tumors are positive for EGFR T790M mutation.
-
Oteseconazole
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Oteseconazole 1340593-59-0 Aug, 2026 Apr.22, 2031 estimated PV Completion – Jun, 2026 [Indication]
For the prevention of recurrent vulvovaginal candidiasis (RVVC) in females who are not of reproductive potential.
-
Obeticholic Acid
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Obeticholic Acid 459789-99-2 37355 Nov.16, 2027 Commercial Production [Indication]
For the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.